SHORT MINI-FUTURE - GILEAD SCIENCES | Delayed Börse Stuttgart 20:42:19 25/06/2024 BST | ||
| 2.86 EUR | +5.54% |
|
| Current month | -15.88% | ||
| 1 month | -12.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 2.86 | +5.54% |
| 24/06/24 | 2.71 | -2.52% |
| 21/06/24 | 2.78 | -6.71% |
| 20/06/24 | 2.98 | -12.87% |
| 19/06/24 | 3.42 | -1.44% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 08:42 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VZ7BHG |
| ISIN | DE000VZ7BHG8 |
| Date issued | 29/10/2014 |
| Strike | 100.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.43 € |
|---|---|
| Lowest since issue | 1.23 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.61
USD
Average target price
82.97
USD
Spread / Average Target
+19.19%
- Stock Market
- Certificates
- Certificat
